InSeal Vascular Closure Device Clinical Study Protocol

Not Applicable

Terminated

• Conditions: Percutaneous Closure of Artery Access Sites
• Interventions: Device: InSeal's Vascular Closure Device

• Registration Number: NCT01896401
• Lead Sponsor: InSeal Medical Ltd.

Brief Summary

The InSeal vascular closure device (VCD)is assessed as percutaneous closure of artery access sites for quick hemostasis and ambulation in patients who have undergone large bore endovascular catheterization procedures.

The study hypothesis is that the VCD is safe and efficaient in achieving hemostasis in the study population.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-02
• Study First Submitted: 2013-07-06
• Study First Submitted QC: 2013-07-06
• Study First Posted: 2013-07-11
• Primary Completion: 2015-08
• Study Completion: 2015-08
• Status Verified: 2016-02
• Last Update Submitted: 2016-02-22
• Last Update Posted: 2016-02-23

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

• Candidate for large bore catheterization procedure (such as TAVI, aortic endograft repair) using a CE approved 18Fr access sheath.
• Subject age is at least 18 years
• Patient has signed most recent approved version of the Informed Consent
• Existence of an additional arterial access port is required in instances where an occluding balloon is planned to be used as a safety precaution.

Exclusion Criteria

• Women Of Child Bearing Potential (WOCBP)
• Legally non-competent patients
• Patient participating in another clinical study at the time of the InSeal VCD study
• Prior target artery closure with a vascular closure device having intravascular component (such as Angio-Seal) 30 days prior to catheterization
• Subjects with known coagulopathy, preexisting hematoma, arteriovenous fistula, or pseudoaneurysm at the vessel access site prior to artery closure
• Patients that do not tolerate aspirin and clopidogrel anticoagulation treatment
• Prior vascular surgery or vascular graft in region of access site
• Significant calcification, atherosclerotic disease, or stent within 1.5 cm of the puncture site that may interfere with the operation of the experimental device

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
InSeal's Vascular Closure Device	InSeal's Vascular Closure Device	Use of the experimental VCD to close the access site of the artery

Primary Outcome Measures

Name	Time	Method
1. Hemostasis within 15 minutes following vessel access site closure and after ACT falls below 200 second	15 minutes

Secondary Outcome Measures

Name	Time	Method
2. Combined rate of closure-device related major adverse events in first month	1 month

Trial Locations

Locations (1)

Cardio Vascular Centrum Frankfurt; 🇩🇪 Frankfurt, Germany